Savsu to supply Novartis’ newly-approved SMA treatment
Savsu Technologies, a New Mexico, US-based company, which creates temperature controlled systems and transport containers developed the evo Cold Chain 2.0 system especially for cell and gene therapies shipments.
Evo ‘smart shippers’ of the Cold Chain 2.0 system were designed to offer thermal stability and to have integrated sensor and communication systems. The containers are connected with evo.is, a cold chain cloud application providing real-time data whilst in transit.
The technology was adopted by AveXis, the developer of Zolgensma (onasemnogene abeparvovec-xioi), which is the first one-time gene therapy for the treatment of spinal muscular atrophy (SMA) in children less than two years old.
Novartis acquired AveXis in April 2018 for $8.7bn (€7.79bn) and led Zolgensma to receive approval from the US Food and Drug Administration (FDA) last month.
Currently, 44% of Savsu’s shares are owned by Biolife Solutions, which also has an exclusive option to purchase all remaining shares.
Mike Rice, CEO of BioLife, commented on the partnership with Savsu, saying that the company looks forward to additional announcements related to new Savsu customers.
